Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Echo Therapeutics, Inc. was a medical technology company focused on developing non-invasive continuous glucose monitoring (CGM) systems for people with diabetes and for use in hospital critical care units. Its lead product candidate was the Symphony tCGM System, designed to provide needle-free glucose readings through the skin using ultrasound and a sensor. The company also developed the Prelude SkinPrep System, a device designed to prepare the skin for transdermal drug delivery by removing the outer layer of the stratum corneum. Despite early promise and technological development, Echo Therapeutics faced significant financial and operational challenges, ultimately leading to a Chapter 7 bankruptcy filing in December 2016. In 2017, its intellectual property and other assets were acquired by an affiliate of Platinum Equity. The company is no longer operating as an independent entity.
Former corporate headquarters, housing executive leadership, administrative functions, and coordinating research and development efforts for its non-invasive medical devices.
The headquarters likely consisted of standard office spaces and potentially laboratory facilities appropriate for a medical device development company. No specific architectural highlights are widely publicized.
As a development-stage medical technology company, the work culture was likely characterized by innovation, a focus on research and clinical trials, and a drive to bring its novel glucose monitoring technology to market. This would have involved a multidisciplinary team of scientists, engineers, and business professionals working in a dynamic, and likely challenging, environment.
This location served as the central hub for strategic decision-making, financial management, and the coordination of product development and clinical activities during the later stages of the company's operations before it ceased.
Echo Therapeutics was primarily focused on the United States market for its product development, clinical trials, and initial commercialization strategy. While potential for international expansion may have been considered as a long-term goal, significant global operations or a widespread international presence were not substantially established before the company ceased its primary activities and filed for bankruptcy. Its efforts were concentrated on gaining regulatory approvals, like FDA clearance, within the US.
One Presidential Boulevard North, Suite 402
Bala Cynwyd
PA
USA
Address: 100 Metro Boulevard, Suite 250, Nutley, New Jersey 07110 (Former HQ)
Served as the primary operational base during a specific period of the company's history, focusing on its core business of medical device development.
Address: 150 Bodwell Street Extension, Avon, MA 02322 (Previously Sontra Medical, later Echo manufacturing/R&D)
Focused on the technical development, engineering, and potentially small-scale production or assembly of its medical device systems.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Echo Therapeutics' leadership includes:
Echo Therapeutics has been backed by several prominent investors over the years, including:
Echo Therapeutics ceased active operations and filed for bankruptcy in December 2016. Therefore, there have been no executive new hires or exits in the last 12 months related to its former operational structure. The company's assets were acquired by Platinum Equity in 2017.
Discover the tools Echo Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Given that Echo Therapeutics is no longer operational and its domain is inactive, the following email formats are based on common structures used by companies and are purely historical/speculative. These formats would no longer be active.
f[last]@echotherapeutics.com (e.g., jdoe@echotherapeutics.com) or [first].[last]@echotherapeutics.com (e.g. jane.doe@echotherapeutics.com)
Format
jdoe@echotherapeutics.com
Example
0 (domain inactive)%
Success rate
Platinum Equity / PR Newswire • February 1, 2017
An affiliate of Platinum Equity announced it had acquired the key assets of Echo Therapeutics, Inc., including its intellectual property portfolio and its Symphony and Prelude product technology. This followed Echo Therapeutics' bankruptcy....more
GlobeNewswire • December 7, 2016
Echo Therapeutics announced that it filed a voluntary petition for relief under Chapter 7 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware. The company intended to pursue an orderly liquidation of its assets....more
PR Newswire • October 13, 2015
Echo Therapeutics reported positive results from a human clinical trial of its next-generation wireless continuous glucose monitoring (CGM) sensor. This news, from when the company was actively developing its technology, highlighted its efforts in advancing non-invasive glucose monitoring....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Echo Therapeutics, are just a search away.